# Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Source: https://onco.cc/trials/nct05872347/  
OnCo record `nct05872347` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SPH4336 in brain and spinal cord tumours, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.

## Summary

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. is a phase 2 interventional study registered as NCT05872347 by Shanghai Pharmaceuticals Holding Co., Ltd, with 52 participants planned, started 2023-09-19 and due to reach its primary completion in 2026-12-31. Interventions recorded: SPH4336 Tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05872347
- Phase: 2
- Setting: A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases.
- Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT05872347: https://clinicaltrials.gov/study/NCT05872347

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- drugs: [SPH4336](https://onco.cc/drugs/sph4336/)
- companies: [GenFleet Therapeutics](https://onco.cc/companies/genfleet/)

---
JSON: https://onco.cc/api/v1/entities/nct05872347.json